Chinese Journal of Lung Cancer 2009 Issue 12 Clinical Observation of Erlotinib in the Treatment of Advanced and Previously Treated Non-small Cell Lung Cancer

Clinical Observation of Erlotinib in the Treatment of Advanced and Previously Treated Non-small Cell Lung Cancer
Junfang TANG;Yunzhong ZHU;Zhe LIU;Wei WU;Zan LIU;Heling SHI;Qiyi MENG;Mingzhi LI;Yuhua WU;Liyan XU

..............page:1276-1281

Role of miRNAs in Lung Cancer
william cs cho; nan juan ; ding yan ; cao zhi cheng

..............page:1312-1315

Advances of Targeted therapies in Non-small Cell Lung Cancer
Ruixiu ZHANG;Yong ZHAO;Zhanque ZHANG

..............page:1359-1364

Observation of Erlotinib in the Treatment of Elderly Patients with Advanced Non-small Cell Lung Cancer and COPD
Qing MA;Li MA;Yan WANG;Fanlu MENG;Linglin ZOU;Huiling ZHANG

..............page:1295-1296

A Retrospective Analysis of Erlotinib and TP/GP Regimen in the Treatment of Advanced Non-small Cell Lung Cancer
Yanxia YANG;Yunqi HUA;Yongjuan WU;Haiqing YUAN

..............page:1301-1304

The Analysis of Erlotinib on Brain Metastases in Patients with Non-small-cell Lung Cancer
Hao BAI;Baohui HAN

..............page:1271-1275

Clinical Study of Erlotinib in the Treatment of Patients with Advanced Stage Non-small Cell Lung Cancer
Tongshan WANG;Jing SUN;Wen GAO;Hua SHEN;Xiaodong LI;Yongmei YIN;Yongqian SHU;Renhua GUO

..............page:1287-1290

EGFR Mutations Detection in Non-small Cell Lung Cancer Tissues by Real-time PCR and DNA Sequencing
Yongwen LI;Hongyu LIU;Ying LI;Yuli WANG;Jing WANG;Jun CHEN;Qinghua ZHOU

..............page:1255-1259

Clinical Observation of Erlotinib as the First-line Treatment for Patients with Advanced Non-small Cell Lung Cancer
Cheng HUANG;Biao WU;Wu ZHUANG;Zhenwu XU;Jing ZHANG;Yunjian HUANG

..............page:1282-1286

The Mechanism of Resistance to EGFR-TKI in NSCLC and Exploration to Overcome the Resistance
Jun PEI;Baohui HAN

..............page:1325-1329

Erlotinib in Patients with Brain Metastases for Non-small Cell Lung Cancer
Jiandong ZHANG;Xinshuang YU;Jinming YU

..............page:1337-1340

Erlotinib as the Second-line Treatment for NSCLC Patients of Stage Ⅲb/Ⅳ
Tian LI

..............page:1297-1300

The Association between EGFR Gene Amplification and the Prognosis in Non-small Cell Lung Cancer: A meta-analysis
Zhijie WANG;Lu YANG;Tongtong AN;Jun ZHAO;Hua BAI;Jianchun DUAN;Meina WU;Minglei ZHUO;Yuyan WANG;Jie WANG

..............page:1247-1254

Biomarkers of Patients with Non-small Cell Lung Cancer who Benefited from Erlotinib Treatment
Dali HAN;Jinmimg YU

..............page:1356-1358

A Clinical Observation of Concomitant Therapy of Erlotinib and Whole Brain Radiotherapy in Patients of NSCLC Combined with Brain Metastases
Jing ZHAO;Qiang FU;Lihong ZHANG

..............page:1291-1294

Molecular Predictor to Response and Toxicity of EGFR-targeted Medicines in Lung Cancer
Cunwei CAI

..............page:1365-1368

A Systematic Review of Erlotinib for Advanced Non-small Cell Lung Cancer
Huiling GUO;Rongfang ZHANG;Qimei YANG;Lingjuan ZHANG;Kehu YANG;Jinhui TIAN

..............page:1260-1265

A Case Report of Erlotinib as First-line Therapy in Extensive Metastatic Patient with Advanced Non-small Cell Lung Cancer
Wanfeng GUO;Xiaoqing LIU

..............page:1374-1376

A Retrospective Study of Erlotinib in the Treatment of 70 Patients with Non-small Cell Lung Cancer
Yuhua WU;Hong TAO;Junfang TANG;Xinyong ZHANG;Yunzhong ZHU;Zhe LIU;Heling SHI;Qiyi MENG;Wei WU;Zan LIU;Lili GUO;Mingzhi LI;Liyan XU

..............page:1309-1311

Progression in Therapy of Erlotinib for Patients with Non-small Cell Lung Cancer
Fanlu MENG;Li MA

..............page:1352-1355

The Impact of Smoking Status on the Efficacy of Erlotinib in Patients with Advanced Non-small Cell Lung Cancer
Yisheng HUANG;Jinji YANG;Yan YANG;Yujuan HUANG;Riqiang LIAO;Yilong WU

..............page:1266-1270

Clinical Observation of Erlotinib in the Treatment of Advanced Non-small Cell Lung Cancer A Report of 92 Eases
Aiqin GU;Liwen XIONG;Huimin WANG;Chunlei SHI;Zhiqiang GAO;Baohui HAN

..............page:1305-1308

Combined Inhibition of Vascular Endothelial Growth Factor and Epidermal Growth Factor Signaling Pathways in Non-small Cell Lung Cancer Therapy
Juan NAN;Qian LIU;Yan DING;Zhanque ZHANG;Allen C.Gao;Qinghua ZHOU

..............page:1316-1324

Mechanisms of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer
Xiaoping LI;Hongjie LI

..............page:1346-1351

Advanced Research on the Response of EGFR Tyrosine Kinase Inhibitors for Non-small Cell Lung Cancer Therapy
Xifeng DONG;Qiang SONG

..............page:1341-1345

Clinical Observation of Erlotnib in the Treatment of Non-small Cell Lung Cancer with Multimetastases in Elderly Patients
Feng ZHANG;Lina XING;You YU;Yanwei MA;Binying ZOU

..............page:1242-1246

qi shi xiao xi

..............page:1228,1241,1246,1254,1259,1275,1286,1315,I-v

Detection and Its Clinical Significance of EGFR Gene Mutation and Gene Amplification in 187 Patients with Non-small Cell Lung Cancer
Hongyu LIU;Ying LI;Gang CHEN;Jing WANG;Yongwen Li;Yuli WANG;Sen WEI;Daxing ZHU;Xiaoming QIU;Weiqiang WANG;Zuoqing SONG;Jun CHEN;Qinghua ZHOU

..............page:1219-1228

Erlotinib-induced Skin Rash in Patients with Non-small Cell Lung Cancer:Pathogenesis, Clinical Significance and Treatment
Yan DING;Qian LIU;Juan NAN;Qinghua ZHOU

..............page:1330-1336

Erlotinib in the trentment of Advanced Non-small-cell Lung Cancer A Systematic Review
Lina ZHU;Zhenjun YANG;Shiyong WANG;Yanming TANG

..............page:1229-1236

Pooled Analysis of the Trials of Erlotinib Monotherapy for Epidermal Growth Factor Receptor (EGFR)-mutant Advanced Non-small Cell Lung Cancer
Ting WANG;Li MA

..............page:1237-1241

Advances of KRAS Mutation in Non-small Cell Lung Cancer
Yang LI

..............page:1369-1373